15 Maggio 2021

NUOVA MODALITA’ PER IL REPORT DI META-ANALISI : “PRISMA STATEMENT ” 2020

METODOLOGIADi Redazione 15 Maggio 2021

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews Matthew J. Page et al. Abstract The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past…

MORTALITA’ PER COVID-19 E PER ALTRE CAUSE ! USA 2020-2021

COVID19 - EVIDENCE, MEDICI DI FAMIGLIA, MEDICINA INTERNA, METODOLOGIADi Redazione 15 Maggio 2021

Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021 Steven H. Woolf et al. A study analyzing US mortality in March-July 2020 reported a 20% increase in excess deaths, only partly explained by COVID-19. Surges in excess deaths varied in timing and duration across states and were…

IL BENEFICIO IN TERMINI DI SOPRAVVIVENZA E’ RIDOTTO AD ASSENTE PER I FARMACI ONCOLOGICI APPROVATI : L’ESPERIENZA CANADESE

EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, GLOBAL HEALTH, METODOLOGIADi Redazione 15 Maggio 2021

Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada Daniel E. Meyers et al. IMPORTANCE Cancer drugs approved by the US Food and Drug Administration have come under scrutiny for marginal clinical benefits; however, the clinical benefits of cancer drugs recommended for reimbursement in Canada have not been adequately…

15 Maggio 2021

NUOVA MODALITA’ PER IL REPORT DI META-ANALISI : “PRISMA STATEMENT ” 2020

MORTALITA’ PER COVID-19 E PER ALTRE CAUSE ! USA 2020-2021

IL BENEFICIO IN TERMINI DI SOPRAVVIVENZA E’ RIDOTTO AD ASSENTE PER I FARMACI ONCOLOGICI APPROVATI : L’ESPERIENZA CANADESE

Impostazioni Cookies